Get the Stockscreener App
3.93
0.76%
-0.03
Pre-market:
3.96
0.03
+0.76%
Cytek Biosciences Inc stock is traded at $3.93, with a volume of 1.55M.
It is down -0.76% in the last 24 hours and up +15.42% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$3.96
Open:
$4.04
24h Volume:
1.55M
Relative Volume:
1.78
Market Cap:
$507.53M
Revenue:
$204.17M
Net Income/Loss:
$-74.00M
P/E Ratio:
-6.8052
EPS:
-0.5775
Net Cash Flow:
$-12.84M
1W Performance:
-2.72%
1M Performance:
+15.42%
6M Performance:
-15.30%
1Y Performance:
+22.05%
1-Day Range:
$3.90
$4.06
1-Week Range:
$3.90
$4.195
52-Week Range:
$2.90
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
3.93 | 507.53M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences (CTKB) director exercises 43,973 RSUs, granted options and RSUs - Stock Titan
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference - GlobeNewswire
Cytek Biosciences debuts Borealis spectral cytometer - SelectScience
Cytek Biosciences Shares Fall After Borealis News and Sales Exit - Bez Kabli
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 - BioSpace
Cytek Biosciences Announces Resignation of Senior Sales Executive - TipRanks
Cytek Biosciences' Philippe Busque resigns as Senior VP, Global Sales and Services - TradingView
Cytek Biosciences, Inc. Announces Resignation of Philippe Busque from Senior Vice President, Global Sales and Services, Effective June 5, 2026 - marketscreener.com
Cytek Biosciences (CTKB) SVP Global Sales and Services to step down June 5, 2026 - Stock Titan
Cytek Biosciences explores new vaccine strategies targeting mucosal immunity - Traders Union
Promising Penny Stocks To Consider In June 2026 - simplywall.st
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Cytek Biosciences launches on-demand webinar on hMSC variation impacting regenerative medicine - Traders Union
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming - Moomoo
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences (CTKB) Edges Higher as Support Holds, Resistance in FocusRSI Overbought Alerts - The Legal Advocate
Cytek Biosciences Q1 2026 Earnings: Deep EPS Miss Fails to Dampen Investor SentimentPre-Announcement Alert - Newser
Cytek Biosciences Reaches US$487m Market Cap Benefiting Insider Stock Buying - 富途牛牛
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):